SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
1.885
+0.115 (6.50%)
Jul 21, 2025, 2:19 PM - Market open

Company Description

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.

The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009.

SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group logo
CountryUnited States
Founded2012
IndustryBiotechnology
SectorHealthcare
Employees15
CEOAngelos Stergiou

Contact Details

Address:
7 Times Square, Suite 2503
New York, New York 10036
United States
Phone646 200 5278
Websitesellaslifesciences.com

Stock Details

Ticker SymbolSLS
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001390478
CUSIP Number81642T209
ISIN NumberUS81642T2096
SIC Code2834

Key Executives

NamePosition
Dr. Angelos M. Stergiou M.D., ScD h.c.Founder, President, Chief Executive Officer and Director
John Thomas Burns CPASenior Vice President and Chief Financial Officer
Dr. Dragan Cicic M.D., MBASenior Vice President and Chief Development Officer
Stacy E. YeungVice President of Legal Affairs, Head of Compliance and Corporate Secretary
Andrew ElnatanSenior Vice President of Regulatory Affairs, CMC and Quality

Latest SEC Filings

DateTypeTitle
Jun 18, 20258-KCurrent Report
Jun 10, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 6, 20258-KCurrent Report
May 15, 2025SCHEDULE 13GFiling
May 13, 20258-KCurrent Report
May 13, 202510-QQuarterly Report
Apr 23, 2025ARSFiling
Apr 23, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 23, 2025DEF 14AOther definitive proxy statements
Mar 20, 20258-KCurrent Report